Abstract:Background: Excessive inflammation and recurrent airway infections characterize people with cystic fibrosis (pwCF), a disease with highly heterogeneous clinical outcomes. How the overall immune response is affected in pwCF, its relationships with the lung microbiome, and the source of clinical heterogeneity have not been fully elucidated. Methods: Peripheral blood and sputum samples were collected from 28 pwCF and an age-matched control group. Systemic immune cell subsets and surface markers were quantified using multiparameter flow cytometry. Lung microbiome composition was reconstructed using metatranscriptomics on sputum samples, and microbial taxa were correlated to circulating immune cells and surface markers expression. Results: In pwCF, we found a specific systemic immune profile characterized by widespread hyperactivation and altered frequencies of several subsets. These included substantial changes in B-cell subsets, enrichment of CD35+/CD49d+ neutrophils, and reduction in dendritic cells. Activation markers and checkpoint molecule expression levels differed from healthy subjects. CTLA-4 expression was increased in Tregs and, together with impaired B-cell subsets, correlated with patients' lung function. Concentrations and frequencies of key immune cells and marker expression correlated with the relative abundance of commensal and pathogenic bacteria in the lungs. Conclusion: The CF-specific immune signature, involving hyperactivation, immune dysregulation with alteration in Treg homeostasis, and impaired B-cell function, is a potential source of lung function heterogeneity. The activity of specific microbes contributes to disrupting the balance of the immune response. Our data provide a unique foundation for identifying novel markers and immunomodulatory targets to develop the future of cystic fibrosis treatment and management.

Update on Innate and Adaptive Immunity in Cystic Fibrosis

Infection and Inflammation in the Cystic fibrosis (CF) airway

Implications for the Microbial Landscape in Cystic Fibrosis

Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions

Aberrant immune programming in neutrophils in cystic fibrosis

Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis

Dysregulation of the Arachidonic Acid Pathway in Cystic Fibrosis: Implications for Chronic Inflammation and Disease Progression

Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis

Widespread alterations in systemic immune profile are linked to lung function heterogeneity and airway microbes in cystic fibrosis

What the future holds: cystic fibrosis and aging

Why don't anti-inflammatories work in cystic fibrosis?

The ageing of people living with cystic fibrosis: what to expect now?

Cystic Fibrosis Lung Disease: An Overview

The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease

Pseudomonas aeruginosa in the Cystic Fibrosis Lung

Increased NFAT and NFκB signalling contribute to the hyperinflammatory phenotype in response to in cystic fibrosis

Role of IL-1β in Experimental Cystic Fibrosis Upon P. Aeruginosa Infection.

CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways

Cystic fibrosis lung environment and Pseudomonas aeruginosa infection

The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosis

A New Frontier in Cystic Fibrosis Pathophysiology: How and When Clock Genes Can Affect the Inflammatory/Immune Response in a Genetic Disease Model